Skip to main content
NUVB
NYSE Life Sciences

Nuvation Bio Completes $287.5M Convertible Note Offering with Full Greenshoe Exercise

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$5.51
Mkt Cap
$1.956B
52W Low
$2.01
52W High
$9.75
52W Position info
174% above low
Off High info
43% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

NUVB has more than doubled off its 52-week low of $2.01.

Summary

Nuvation Bio announced the full exercise of the over-allotment option for its convertible senior notes, increasing the total offering size to $287.5 million and securing approximately $277.6 million in net proceeds.


Key Events · Financing and Capital Events · NUVB

  • Greenshoe Option Fully Exercised

    Underwriters fully exercised the over-allotment option for an additional $37.5 million in 0.75% Convertible Senior Notes due 2032.

  • Total Offering Reaches $287.5 Million

    The full exercise brings the total aggregate principal amount of notes sold in the offering to $287.5 million, up from the initial $250 million.

  • Net Proceeds of $277.6 Million

    The company estimates net proceeds from the total offering, inclusive of the greenshoe, to be approximately $277.6 million after deducting expenses.

  • Dilution Mitigation via Capped Calls

    Nuvation Bio entered into additional capped call transactions with a cap price of $10.4580 per share (an 80.0% premium over the June 25th stock price) to reduce potential dilution upon conversion.


Analysis · NUVB · Life Sciences

This 8-K finalizes Nuvation Bio's significant capital raise, confirming the full $287.5 million in convertible senior notes after underwriters exercised their greenshoe option. The additional $37.5 million in proceeds, combined with the initial offering, provides substantial funding for general corporate purposes. The low interest rate, high conversion premium, and capped call transactions help mitigate potential dilution, making this a relatively favorable financing for the company.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NUVB was trading at $5.51 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $2.01 to $9.75. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NUVB - Latest Insights

NUVB
Nov 04, 2026, 4:05 PM EST
Source: PR Newswire
Importance Score:
7
Price at Filing: $4.78
Real-time Price: $3.99 info
Change: -$0.7889 (-17%) info
Market Cap: $1.413B info
NUVB
Sep 17, 2026, 7:30 AM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $5.78
Real-time Price: $3.99 info
Change: -$1.79 (-31%) info
Market Cap: $1.413B info
NUVB
Aug 20, 2026, 8:00 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $7.23
Real-time Price: $3.99 info
Change: -$3.24 (-45%) info
Market Cap: $1.413B info
NUVB
Aug 06, 2026, 7:53 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $6.16
Real-time Price: $3.99 info
Change: -$2.17 (-35%) info
Market Cap: $1.413B info
NUVB
Aug 06, 2026, 6:55 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $6.01
Real-time Price: $3.99 info
Change: -$2.02 (-34%) info
Market Cap: $1.413B info